The follicular (FO) versus marginal zone (MZ) B cell fate decision in the spleen depends upon BCR, BAFF, and Notch2 signaling. Whether or how Gi signaling affects this fate decision is unknown. Here, we show that direct contact with Notch ligand expressing stromal cells (OP9-Delta-like 1) cannot promote normal MZ B cell development when progenitor B cells lack Gαi proteins, or if Gi signaling is disabled. Consistent with faulty ADAM10-dependent Notch2 processing, Gαi-deficient transitional B cells had low ADAM10 membrane expression levels and reduced Notch2 target gene expression. Immunoblotting Gαi-deficient B cell lysates revealed a reduction in mature, processed ADAM10. Suggesting that Gαi signaling promotes ADAM10 membrane expression, stimulating normal transitional B cells with CXCL12 raised it, while inhibiting Gαi nucleotide exchange blocked its upregulation. Surprisingly, inhibiting Gαi nucleotide exchange in transitional B cells also impaired the upregulation of ADAM10 that occurs following antigen receptor crosslinking. These results indicate that Gαi signaling supports ADAM10 maturation and activity in transitional B cells, and ultimately Notch2 signaling to promote MZ B cell development.
Keywords: heterotrimeric g-protein, notch2, aDaM10, B lymphocyte, marginal zone inTrODUcTiOn The fetal liver and the bone marrow support B1 and B2 lymphocyte development (1, 2) . Fetal liver hematopoietic progenitors give rise to long-lived B1 B lymphocytes, which predominately reside in serosal lined cavities and in the spleen. As hematopoiesis shifts from the fetal liver to the bone marrow, B1 B cell production largely ceases, and bone marrow progenitors produce B2 cells, which have two developmental fates that are not realized until the newly formed B cells traffic to the spleen. These recent splenic arrivals are termed transitional B cells and they express B220, CD19, IgM, and CD93 (3). They must undergo a second tolerance checkpoint and will eventually mature to a follicular (FO) or a marginal zone (MZ) B cell (4) . FO B cells reside in lymphoid follicles and continuously recirculate between lymphoid organs. MZ B cells do not recirculate but can shuttle between the splenic MZ and follicles (5) . They have a limited antigen receptor repertoire, largely specialized to recognize encapsulated bacteria and polysaccharide antigens in a T cell-independent fashion (6) .
Precisely when the B2 cell developmental fate is assigned in the spleen has been controversial (7) (8) (9) . Bone marrow-derived B cell progenitors enter the marginal sinus and red pulp of the spleen and are termed transitional B cell type 0 (T0) cells (10) . T0 cells migrate from the MZ sinus into the splenic white pulp, where they acquire surface IgD becoming T1 cells. T1 cells that gain CD23 are termed transitional B cell type 2 (T2) cells and their survival is highly BAFF dependent (11) . Based on high or low expression of CD21, T2 cells are divided into T2-MZ and T2-FO, respectively (3) . As designated, these cells are biased to become FO or MZ B cells; however, the commitment to a MZ or FO B cell phenotype likely occurs before the T2 stage. A recent study exploring the loss of MZ B cells in thousand-and-one amino acid kinase (TAOK) 3-deficient mice found that wild-type T1 cells bearing surface ADAM10 exclusively differentiated into MZ B cells, while ADAM10 surface-negative T1 cells gave rise to both FO and MZ B cells (12) .
A variety of genetic mutations bias B2 B cell differentiation toward either a MZ or FO B cell fate (13) (14) (15) (16) (17) (18) . These mutations largely impact Notch2, BCR, or BAFF signaling. A MZ fate requires the engagement of Notch2 on transitional B cells by Delta-like 1 (DL1). Splenic fibroreticular cells located in the white pulp express DL1 and their genetic ablation blocks MZ B cell development (19) . Ligand binding to Notch2 induces an ADAM10-dependent cleavage that allows a subsequent intramembranous cleavage by γ-secretase. ADAM10 −/− mice lack MZ B cells (14, 20) . The ADAM10 and γ-secretase-mediated cleavages releases the intracellular domain of Notch2 (NICD2), which enters the nucleus to interact with DNA-binding proteins to activate Notch2 target genes. Notch2 along with nuclear factor-κB (NF-κB) activation downstream of the BAFF receptors instructs a MZ fate (21) . BCR signaling during positive selection may also impact the B2 cell fate decision as weak signals promote MZ B cell development while stronger signals bias the cells toward a FO B cell, perhaps by tuning the sensitivity of the cells to Notch2 signaling (15, 22) . The loss of Gαi proteins in developing B cells severely reduces MZ B cell numbers; however, whether or how this loss affects the MZ versus FO B cell fate decision is unknown (23, 24) .
In B cells, the absence of Gαi2 markedly reduces the available pool of Gi proteins, and the additional loss of Gαi3 depletes it, disabling chemoattractant receptor signaling (24) . Surprisingly, the absence of the three highly expressed B cell chemoattractant receptors CXCR5, CCR7, and EBI2, whose combined loss completely disrupts the splenic lymphoid architecture, did not cause a loss of phenotypic MZ B cells (25) . Two G protein-coupled receptors (GPCRs) have been linked to MZ B cell positioning and retention, the cannabinoid receptor CB2 and the sphingosine 1-phosphate receptor 1 (S1PR1). Genetic targeting CB2 reduced MZ B cell numbers, while the loss of S1PR1 had no impact (5, (26) (27) (28) . Despite the reduction in MZ B cells, the loss of CB2 did not affect BCR or Notch2 signaling (26) . Targeting another GPCR, GPR97, caused an expansion of MZ B cells at the expense FO B cells, perhaps by affecting NF-κB activity (29) . Together, the GPCR gene targeting data suggest that the loss of Gαi in B cells causes the loss of MZ B cells due to their failure to be retained in the MZ, rather than impacting MZ B cell development.
In this study, we tested whether the loss of Gαi proteins directly affected MZ B cell development. We show that despite the direct exposure to Notch2 ligand expressing cells, neither Gαi-deficient nor pertussis toxin (PTX)-treated progenitor B cells properly differentiate to MZ B cells. Favoring an intrinsic defect in Notch2 signaling, the Gαi-deficient transitional B cells have low levels of surface ADAM10 and of Notch2 target genes. Furthermore, treating B cell progenitors with PTX causes a partial T1-T2 transition block and inhibited the normal increase in ADAM10 that occurs on transitional B cells. The significance of these results is discussed. fl/fl mice on a mixed background have been described previously and were backcrossed 10 times on to C57BL/6J. The C57BL/6 mb1-cre mice were kindly provided by Dr. Michael Reth (University of Freiburg, Germany). For those experiments that directly compared WT and gene targeted mice, littermate controls were used when possible. Otherwise age and sex matched mb1-cre, vav1-cre, ric8 fl/fl , or Gnai2 fl/fl mice served as controls. All mice were used in this study were 6-14 weeks of age. Mice were housed under specific-pathogen-free conditions. All the animal experiments and protocols used in the study were approved by the NIAID Animal Care and Use Committee at the National Institutes of Health.
MaTerials anD

cells and cell culture
OP9 control and OP9-DL1 cells were obtained from Dr. JuanCarlos Zúñiga-Pflücker (University of Toronto) and maintained in α-MEM containing 20% fetal calf serum (FCS), antibiotics (100 IU/ml penicillin and 100 µg/ml streptomycin), 1 mM sodium pyruvate, and 50 µM 2-mercaptoethanol. Splenic B cells were isolated by negative depletion using biotinylated antibodies to CD4, CD8, CD11b, and CD11c and Dynabeads M-280 Streptavidin (Thermo Fisher Scientific). The B cell purity was greater than 95%. When needed B cells were cultured in RPMI 1640 containing 10% FCS (Gibco), 2 mM l-glutamine, antibiotics (100 IU/ml penicillin and 100 µg/ml streptomycin), 1 mM sodium pyruvate, and 50 µM 2-mercaptoethanol. Bone marrow cells were cultured in complete Iscove's Modified Dulbecco's Medium (GIBCO) in the presence of IL-7 (20 ng/ml) for 4 days to enrich for IgM + immature B cells. On occasion, PTX (200 ng/ml) was added for the terminal 2 or 24 h of the culture. Subsequently, cells were washed twice with PBS and plated at 1 × 10 6 cells/ml with 20 ng/ ml of recombinant mouse BAFF (R&D Systems) in co-culture with OP9 or OP9-DL1 cells. The following were added, or not, to the cultures: Gallein (various concentrations, Tocris Bioscience), IBMX (1 µM, 3-Isobutyl-1-methylxanthine, Sigma-Aldrich), terbutaline (10 nM, Sigma-Aldrich), AM630 (1 µM, Tocris Bioscience), AMD3100 (1 µg/ml, Sigma-Aldrich), and CXCL12 (1 µg/ml, R&D Systems). The chemical compounds and BAFF were re-added on alternative days for the duration of the culture.
Flow cytometry and antibodies
Single cells were resuspended in PBS, 2% FBS, and stained with fluorochrome-conjugated or biotinylated antibodies against B220 (RA3-6B2), IgD (11-26c-2a 
intracellular Flow cytometry
Labeling of dead cells, fixation, and permeabilization were performed as described in the manufacturer's protocol. For the ADAM10 upregulation and detection of the level of phosphorylated signaling molecules, total splenocytes or purified B cells were rested in DMEM containing 1% FCS antibiotics (100 IU/ml penicillin and 100 µg/ml streptomycin), 1 mM sodium pyruvate, and 50 µM 2-mercaptoethanol for 30 min at 37°C/5% CO2 before stimulation with 1 µg/ml CXCL12 (R&D Systems) or α-IgM [F(ab′)2 Fragment goat Anti-mouse IgM, μ chain specific; Jackson ImmunoResearch]. Depending upon the experiment, cells were surface stained with anti-B220, anti-CD19, anti-CD21, anti-CD23, IgD, IgM, and anti-CD93 for 30 min at 4°C and following permeabilization, with anti-pTaok1-3 (EPR4883; Abcam), antipBTK-PE (N35-86; BD Biosciences), anti-pCREB-AlexaFluor 488 (J151-21; BD Biosciences), anti-pSyk-PE (moch1ct; Thermo Fisher Scientific), or pAkt Alexa Fluor 647 (D9E; Cell Signaling Technology) for 30 min at room temperature. For detection of pTAOK1-3, we used secondary F(ab′)2 fragment of goat antiRabbit IgG(H + L) (Thermo Fisher Scientific). Cells were finally resuspended in 250-µl 1% BSA/PBS and filtered prior to acquisition on a FACS Canto II flow cytometer (BD Biosciences).
rna isolation and real-Time qPcr
Splenic B-cell subsets were sorted, and RNA was isolated using the TRIzol (Thermo Fisher Scientific) according to the manufacturer's instructions. Complementary DNA was synthesized using oligo(dT) and Omniscript RT (Qiagen) from 500 ng or 1 µg of total RNA. The real-time PCR primers used to amplify genes are listed below while those for Dtx1, Id2, Id3, Bcl3, Btk, Hes1, and Rpl27 were from Qiagen (QuantiTect primer QT00097139, QT01038870, QT00248185, QT00247583, QT00102179, QT00313537, and QT02328683, respectively). Real-time PCR was performed using a QuantStudio 3 Real-Time PCR System (Thermo Fisher Scientific) following the Rotor-Gene SYBR Green PCR kit (Qiagen) protocol. All results are expressed as 2
−ΔΔCt
, where ΔΔCt = (Cttarget − CtRpl27) for treated samples-(Cttarget − CtRpl27) for control cells. Ct stands for cycle threshold. Data are shown as the mean ± SEM.
immunoblotting
The cells were lysed in RIPA buffer (Sigma-Aldrich) with 1 mM NaF, 1 mM PMSF, 1 mM DTT, and 1 mM Na3VO4 with complete and PhosSTOP inhibitors (Sigma-Aldrich). The lysates were separated by SDS-PAGE and transferred to nitrocellulose membranes by the iBLOT gel transfer system (Thermo Fisher Scientific). The membrane was incubated with 5% non-fat milk (w/v) in TBS buffer [25 mM Tris-HCl (pH 7.5), 150 mM NaCl, 0.1% Tween 20] for 1 h and then reacted with the primary Ab in TBS buffer with 2.5% non-fat milk or 5% BSA (w/v) for overnight by shaking at 4°C. The appropriated second Abs conjugated to HRP were used to detect the protein of interest via ECL. The following antibodies were used: ADAM10 (EPR5622; Abcam), Notch2 (C651.6DbHN-c; Developmental Studies Hybridoma Bank), pTAOK1-3 (EPR48883; Abcam), anti-actin-HRP conjugate (Sigma-Aldrich), Goat anti-rabbit IgG (H + L)-HRP conjugate #7074, 1:3,000 (Cell Signaling); and horse anti-mouse IgG, HRP-linked antibody #7076, 1:3,000 (Cell Signaling).
chemotaxis assays
Chemotaxis assays were performed using a transwell chamber (Costar). Briefly, splenic B cells were immunostained for B cell subsets with fluorochrome-conjugated antibodies against B220, CD21, and CD23; washed twice, resuspended in complete RPMI 1640 medium, and added in a volume of 100 µl to the upper wells of a 24-well transwell plate with a 5-µm insert. Lower wells contained various concentrations of CXCL12 or CXCL13 (R&D Systems) in 600 µl of complete RPMI 1640 medium. The numbers of cells that migrated to the lower well after 2 h incubation were counted using a MACSQuant flow cytometer (Miltenyi Biotec). The percent migration was calculated as the numbers of cells that migrated into the lower part of the chamber divided by the total number of cells in the starting cell suspension, and multiplying the results by 100.
imagestream (is): labeling, acquisition, and analysis
The splenic B cells were stained with B220 PE conjugated, CD21 e450 conjugated and CD23 PE-cy7 conjugated for 10 min then fixed using 2% paraformaldehyde. The p65 subunit of NF-κB was visualized by indirect labeling. The primary Rabbit polyclonal NF-κB/p65 antibody (SantaCruz Biotechnology) was diluted 1:50 in 3% BSA, and 0.1% Triton X-100 in PBS and added to 1 × 10 6 fixed cells. Samples were incubated for 2 h at room temperature. Primary antibody was washed and 1:200 dilution of secondary Alexa488-conjugated donkey anti rabbit IgG antibody (Jackson ImmunoResearch Laboratories Inc.) was added and incubated at room temperature in the dark for 1 h. Secondary antibody was removed, and cells resuspended in 100 µl PBS. Just prior to running on the IS, all samples had Draq5 (Cell Signaling) added (20 nM final concentration), to visualize the nucleus. At least, 20,000 events were collected for all samples on an IS MarkII using 488, 405, and 642 nm laser excitations. Cell populations were hierarchically gated for single cells that were in focus and were positive for both Draq5 and p65. Then, based on Draq5 intensity histogram, cells were gated on those that were in G0 and G1/S phase to avoid cells that have a disrupted nuclear membrane. After those gates were applied at least 1,000 cells per group were acquired (follicular: B220
, and MZ: B220
. Following data acquisition, the spatial relationship between the NF-κB and nuclear images was measured using a feature (ratio translocation) calculated in the IDEAS software package. The "Ratio translocation" feature, is the ratio of NF-κB intensity in the nuclear mask over NF-κB intensity in the whole cells (calculated using the brightfield mask) expressed as the percentage. Nuclear mask was defined based on Draq5 intensity where a signal was considered specific when it was a least 20 times higher than the background. The shift in the distribution between two populations (e.g., control versus treated cells) was tested using the Fisher's Discriminant ratio calculated using Graphpad Prism software. A cell was considered with a nuclear p65 NF-κB when the "Ratio translocation" was greater than 60%.
statistics
In vivo results represent samples from three to nine mice per experimental group. Results represent mean values of at least triplicate samples. SEMs and p values were calculated with t-test or two-way ANOVA using GraphPad Prism (GraphPad software).
resUlTs
Models of gα i Deficiency and loss of MZ B cells
To better understand the role of Gαi proteins in MZ B cell development in mice, we used several different mouse lines. Mice with a B cell-specific loss of Gαi2 were generated by crossing Gnai2 fl/fl mice to mb1-cre mice. Double knockout (DKO) mice, which lack both Gαi2 and Gαi3 in their B cells were developed by crossing Gnai3 −/− mice to the Gnai2 fl/fl mb1-cre mice (24) . We also crossed the mb1-cre mice to the ric8 fl/fl mice. Ric-8A functions as a chaperone and guanine nucleotide exchange factor for a subset of G protein α subunits including Gαi. The B cell specific loss of Ric-8A causes a marked reduction in B cell expression of Gαi2 and Gαi3 (30) . Finally, we deleted Gnai2 in hematopoietic cells using vav1-cre, which results in the loss of Gnai2 at all stages of B cell development (31) . To compare MZ development in these various mouse strains, we prepared spleen cells from them and analyzed cells in the B220 gate for their expression of CD21 and CD23. MZ (24, 30, 31) . A detailed picture of the % of cells among the different splenic B cell subsets in the various Gαi-deficient mice is shown in Table 1 . Next, we assessed the status of BTK by examining the levels of BTK phosphorylated on Y223 in transitional and FO B cells. Located in the BTK SH3 domain, this is an autophosphorylation site, whose phosphorylation occurs following Src kinase Y511 transphosphorylation and that can be induced by IgM crosslinking (33) . Normalized to the WT T0 cells, the WT T1 and T2, and FO cells had a 19, 53, and 48% increase in pBTK, respectively ( Figure 1F ). Compared to their respective wild-type fractions, the DKO T0 and T1 fractions had an approximately 12% decrease in pBTK, the DKO T2 cells had a similar level, while the DKO FO B cells had a 35% increase. Overall, these results do not support a role for enhanced BCR signaling in the Gαi-deficient B cell transitional B cells as a contributing factor to the lack of MZ B cells in these mice.
Decreased notch signaling in B cells lacking gα i expression
Upon entering the splenic white pulp, T0 B cells acquire surface IgD and develop to T1 B cells (10) . However, Gαi-deficient B cells have difficulty entering the white pulp (24) . Consistent with this defect, the Gαi-deficient B cells exhibit a partial T0 to T1 transition block. This can be visualized by flow cytometry by gating on the B220, IgM, and CD93-positive cells and plotting IgD versus CD23. Such profiles show an increased ratio between the T0 
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and T1 cells from the Gnai2
fl/fl mb1-cre, ric8 fl/fl mb1-cre, and DKO mice as compared to the same ratio using cells from the WT and Gnai3 −/− mice (Figure 2A) . Furthermore, the Gαi-deficient T1 and T2 transitional B cells expressed a lower level of surface IgD than did the WT transitional B cells (Figure 2B) . A failure to properly enter the white pulp could limit Gαi-deficient B cells from contacting the Notch ligands present on CCL19-expressing follicular fibroblasts (19) . To assess whether the Gαi-deficient B cells had received inadequate Notch signals, we first checked CD21 expression on transitional and FO B cells from WT and DKO mice. A known Notch2 target gene, the CD21 gene has binding sites for Rbp-J, a DNA-binding protein to which the NICD binds (34) . Consistent with an early impairment in Notch signaling, the DKO transitional B cells had reduced levels of CD21 expression compared to control cells ( Figure 2C) . Next, we used RT-PCR to check the expression of several other Notch target genes including hairy and enhancer of split-1 (Hes1), Deltex1 (Dtx1), and inhibitor of DNA binding 2 (Id2). Hes1 is a basic helix loop helix transcription factor activated by Notch signaling, while Dtx1 is a ubiquitin ligase that regulates Notch signaling (35) . Id2 and Id3 inhibit the DNA-binding activity of E proteins, transcription factors important for B cell development and differentiation (36) To determine whether the Gαi-deficient B cells express normal levels of Notch2, we first examined B cell lysates by Notch2 immunoblotting, which revealed no differences in the level of unprocessed Notch2 or the N2-Ext domain (Figure 2E ). To assess Notch2 surface expression, we used flow cytometry. We found similar levels of Notch2 expression on WT and DKO bone marrow progenitors (Figures 2A-E) and recirculating B cells (Figure 2F ) (data not shown). Next, we checked various splenic B cell populations (Figure 2F ). WT and DKO T0, T1, and FO splenic B cells also expressed similar levels. We did note a slight enhancement in Notch2 expression on the DKO T2 cells, and a reduced level on the DKO MZ precursor (MZP) cells. Thus, the reduction in Notch2 target genes noted in the Gαi-deficient B cells cannot be explained by inadequate levels of Notch2 expression at the plasma membrane.
To test whether we could restore MZ B cell development by ensuring access to Notch ligands, we used a previously describe in vitro assay of splenic B cell development (37) . Non-adherent bone marrow cells that had been cultured for 4 days with Il-7 (>95% B220 + CD19 + CD93 + ) were plated on a stromal cell line that expresses a Notch ligand (OP9-DL1) or not (OP9), in the presence of BAFF. Phenotypic T0, T1, and T2 cells were evident 2 days later, and phenotypic FO and MZ shortly thereafter (data not shown, see below). By 7 days, approximately 15-25% of the recoverable cells had a MZ B cell phenotype. As expected, few if any MZ B cells appeared in the OP9 cultures. By contrast, directly plating the Gαi-deficient B cell progenitors on the OP9-DL1 cells did not rescue normal MZ B cell development (Figures 3A,B) . These data argue that the Gαi-deficient transitional B cells are less sensitive to Notch ligands. gα i nucleotide exchange, but not gβγ signaling, is needed for MZ B cell Development in OP9-Dl1 cultures
To provide further evidence that Gαi signaling is needed for MZ B cell development we made use of PTX, which ADP ribosylates Gαi proteins preventing receptor triggered Gαi nucleotide exchange. This inhibits Gβγ subunit release from the heterotrimeric G-protein, thereby blocking the activation of downstream effectors of Gαi-GTP and Gβγ (38) . When we treated bone marrow B cell progenitors with PTX, prior to plating them on OP9-DL1 cells, we found a sharp reduction in the appearance of phenotypic MZ B cells. Initially, we added PTX during the final 24 h of the IL-7 culture, but subsequently, showed that a 2-h exposure had a similar inhibitory effect ( Figure 3C) . To assess the importance of Gβγ subunit release, we employed Gallein, a small molecule inhibitor of many Gβγ triggered signaling pathways including chemotaxis (39) . We first established that Gallein inhibited B cell chemotactic responses (Figure 3D ). It did, as a 20-µm concentration reduced B cell chemotaxis to either CXCL12 or CXCL13 by approximately two-thirds. However, repeatedly adding a similar concentration to the OP9-DL1 B cell cultures did not adversely affect MZ B cell development (Figure 3E ). This result argues that a Gβγ effector function unaffected by Gallein treatment, or that a Gαi-GTP effector helps mediates MZ B cell development. Since the loss of Gαi can affect intracellular cyclic adenosine monophosphate (cAMP) levels by allowing the unopposed action of Gαs, we assessed the impact of raising intracellular cAMP levels in the OP9-DL1 cultures. IBMX increases cAMP by inactivating cAMP phosphodiesterases while the β-adrenergic receptor agonist terbutaline raises cAMP via Gαs-mediated activation of adenylyl cyclases. While both compounds reduced the appearance of MZ B cells, neither approached the efficacy of PTX (Figure 3F) . We also tested the impact of limiting CXCR4 or CB2 signaling by adding specific antagonists, AMD3100 and AM630, respectively (40, 41) . However, both compounds had a negligible impact on MZ B cell development in the OP9-DL1 system ( Figure 3F) . We did note that adding CXCL12 slightly raised the % of MZ B cells at the termination of the culture although the difference did not reach significance. One caveat in interpreting these experiments, not only the progenitor B cells, but also the OP9-DL1 cells were exposed to the different compounds. However, this is unlikely an issue in the PTX experiments, as we exposed the progenitor B cells to PTX prior to adding them to the OP9-DL1 cells. Finally, to assess whether the loss of Gαi proteins altered cAMP signaling in vivo, we checked phosphorylated protein kinase A and phosphorylated CREB levels in the WT and DKO transitional B cells by flow cytometry (Figure 3G) . We found no significant differences between WT and DKO transitional B cells in this regard. Thus, while elevated cAMP levels may adversely affect MZ B cell development they are unlikely to account for the lack of MZ B cells when B cells lack Gαi proteins.
reduced aDaM10 expression in gα i -Deficient Transitional B cells
Diminished Notch2 target gene expression following direct exposure to Notch2 ligands suggests defective Notch2 processing in the Gαi-deficient cells. We focused on ADAM10, whose activity releases the extracellular domain of Notch2 allowing γ-secretase to release the NICD2. The ADAM10 metallopeptidase functions not only to cleave the extracellular domain of Notch2 but also other surface membrane proteins including CD23 and ICOS ligand (42, 43) . Consistent with a defect in ADAM10 sheddase activity, we found elevated levels of both membrane proteins on the Gαi-deficient T2 cells compared to WT cells ( Figure 4A) . Immunoblotting ADAM10 in cell lysates from WT and DKO B cells revealed that the DKO B cells had reduced levels of ADAM10, and impaired ADAM10 processing ( Figure 4B) . Maturation of ADAM10 requires removal of the prodomain by either Furin or PC7. The prodomain functions as a molecular chaperone important for the localization of the catalytic domain to the cell membrane (44) . The DKO B cell lysates had 50% less processed ADAM10 compared to the WT B cell lysates. To assess ADAM10 surface expression, we used flow cytometry comparing both bone marrow and splenic B cell subsets. This analysis showed a reduction in ADAM10 expression on the DKO bone marrow Fr. B/C, Fr. D., and Fr. E cells and on DKO splenic T0 and T1 cells, and MZPs ( Figure 4C ). Of note, the Gαi-deficient T2 cells had elevated CD23 and ICOS ligand levels despite having ADAM10 levels equivalent to the WT T2 cells. This may reflect the reduced ADAM10 levels on the Gαi-deficient T1 cells or reduced ADAM10 activity despite a similar expression levels.
In the study of Taok3 we checked the status of pTAOK1-3 by flow cytometry using a monoclonal antibody that recognizes phosphorylated S181 in TAOK1 and 2, and S177 in TAOK3 (Figure 4E ). We found a small reduction in the amount of phosphorylated TAOK1-3 in the DKO T0 and T1 cells. Thus, the poor ADAM10 expression on T0 and T1 cells in the spleen helps to explain the defective MZ B cell development in mice whose B cells lack Gαi2 or Gαi2 and Gαi3.
Both cXcr4 engagement and anti-igM crosslinking increase TaOK, BTK, and creB Protein Phosphorylation in Transitional T0 and T1 cells Next, we compared the effect of CXCL12 and anti-IgM on the phosphorylation status of TAOK proteins in various B cell subsets with a focus on transitional B cells. To do so, we exposed wild-type B cells to either anti-IgM or to CXCL12 and used flow cytometry to monitor pTAOK proteins in the different splenic B cell subsets ( Figure 5A) . We found that a 15-min exposure to either stimulus increased pTAOK1-3 in T0 and T1 cells, although anti-IgM proved more potent. Anti-IgM stimulation also raised the pTAOK1-3 levels in T2, MZP, and MZ B cells while CXCL12 did not. For comparison, we checked the same stimuli on the levels of pBTK and pCREB. Mice lacking BTK have a defect in the T2 to FO B cell transition, but do not have defective MZB cell development (46) . We found that anti-IgM treatment triggered increases in pBTK levels in all B cell populations apart from FO B cells, while CXCL12 increased pBTK levels in all the B cell populations except for T0 and FO B cells. In each instance, CXCL12 triggered a lower, and less sustained response than did BCR crosslinking (Figure 5B) . In non-hematopoietic cells, CREB phosphorylation has been linked to ADAM10 processing (47) . We found that anti-IgM and CXCL12 increased pCREB levels in all the splenic B cell subsets although again BCR crosslinking led to higher, more sustained responses ( Figure 5C ). These results indicate that chemoattractant receptor and BCR signaling activate a partially overlapping set of signaling intermediates in transitional B cells.
cXcl12 or Bcr crosslinking raises aDaM10 levels on WT T0/T1 B cells, but not on gα i -Deficient T0/T1 B cells
In the previous study of Taok3 −/− mice, the analysis of wild-type, transitional B cells following BCR crosslinking ADAM10 translocated from the cytosol to the plasma membrane as assessed by immunocytochemistry (12) . We performed a similar analysis although we followed ADAM10 membrane expression on transitional B cells by flow cytometry after exposure to anti-IgM or CXCL12. We found that both stimuli triggered increased ADAM10 expression on a subset of T0 and T1 B cells, while ADAM10 levels rose variably on T2 B cells, and not at all on FO B cells in response to the same stimuli. Shown are flow cytometry patterns from an experiment where anti-IgM induced a particularly strong increase in ADAM10 expression ( Figure 6A , and data not shown). Next, we compared the response of WT and Gnai2 fl/fl vav1-cre B cells to CXCL12 or anti-IgM. As expected, the Gαi-deficient B cells failed to mobilize ADAM10 to the cell surface following stimulation with CXCL12; however, surprisingly anti-IgM treatment also failed to raise ADAM10 expression on the Gαi-deficient T0/T1 B cells. By contrast, anti-IgM did increase ADAM10 expression on T2 B cells from the same Gαi-deficient mice ( Figure 6B ). To confirm these results, we assessed whether blocking Gαi signaling in WT transitional B cells would also inhibit anti-IgM-induced upregulation of ADAM10, which it did ( Figure 6C) . In contrast to the Gnai2 fl/fl vav1-cre T2 cells, the PTX-treated WT T2 did not respond to antigen receptor crosslinking. As expected, PTX treatment reduced the CXCL12-induced increases in pBTK levels in the T0, T1, and T2 cells (Figure 6D) . In contrast to the sharp reduction in ADAM10 expression following exposure of the transitional B cells to anti-IgM, pBTK levels were minimally affected by the PTX treatment ( Figure 6D) . Thus, the loss of Gαi proteins or Gαi signaling not only impairs the upregulation of ADAM10 on T0/T1 B cells in response to CXCL12 but also following BCR crosslinking.
The increase of aDaM10 levels in OP9-Dl1 cultures Depends Upon gα i signaling
To further test the impact of BCR and Gαi signaling on developing wild-type transitional B cells, we used bone marrowderived B cell progenitors and the OP9-DL1 system. Following culture with IL-7 for 4 days, the bone marrow cells were 95% CD19 + B220 + CD93 + . These cells lacked CD21 and CD23 expression, one-third expressed surface IgM, and of those one-half expressed IgD. Approximately 3% of the CD19 + CD93
+ IgM + cells expressed ADAM10 ( Figure 7A ). These cells were plated on OP9-DL1 cells in the presence of BAFF. Prior to plating we treated some cells with PTX for 2 h or not. To others cultures, we added CXCL12, anti-IgM, anti-IgM plus CpGs, or Ibrutinib, which inhibits Bruton's tyrosine kinase (48) . We analyzed the cells 2 days later. First, we assessed the relative percentage of T0, T1, and T2 cells finding that PTX, anti-IgM, anti-IgM plus CpGs, and Ibrutinib to varying degrees inhibited both the T0-T1 and T1-T2 transition. By contrast, the addition of CXCL12 had no effect ( Figure 7B) . Next, we analyzed the impact of the same stimuli on ADAM10 expression on developing T0 and T1 cells. We found that PTX, anti-IgM, and anti-IgM plus CpGs caused a reduction in the % of CD81 + ADAM10 + cells, while CXCL12 and Ibrutinib had no effect (Figures 7C,D) . These results indicate that Gαi signaling supports ADAM10 expression on T0 and T1 B cells, providing a mechanism by which either constitutive Gαi signaling or the engagement with GPCR ligands can promote MZ B cell development. By contrast, the persistent exposure of progenitor and transitional B cells to surface Ig crosslinking interferes with T0-T1 and T1-T2 transitions and blocks ADAM10 membrane expression.
Finally, we confirmed the importance of Gαi proteins in ADAM10 expression by checking the acquisition of ADAM10 by developing WT and Gαi-deficient B cells in the OP9-DL1 system. Following culture with IL-7 for 4 days, bone marrow cells from either control (Gnai2 fl/fl or mb1-cre) mice or from the DKO mice were plated on OP9-DL1 cells in the presence of BAFF. We analyzed the cells prior to plating on the OP9-DL1 cells, also one (data not shown), and 2 days after plating. Representative flow cytometry patterns demonstrating CD93 versus CD19 expression, IgM versus CD23, IgD versus CD23 on IgM + gated cells, and ADAM10 versus CD81 on T0, T1, and T2 cells are shown (Figures 8A,B) . Following culture with IL-7, nearly all the WT and DKO bone marrow cells expressed CD19 and CD93. However, a lower percentage of the DKO progenitors expressed surface IgM as compared to wild-type B cell progenitors. Among the WT and DKO IgM-positive cells, IgD levels appeared similar. We found a slight reduction in ADAM10 expression on the day 0 DKO T0 and T1 cells. After 1 day of culture on the OP9-DL1 cells, ADAM10 expression increased on the WT transitional B cells, while we noted little to no increase on the DKO T0-T2 B cells. After 2 days of culture, Figure 8C) . Thus, the inability of the Gαi-deficient progenitors to efficiently upregulate ADAM10 expression likely explains the lack of MZ B cell development in these cultures. 
DiscUssiOn
Whether or how Gαi proteins promote MZ B cell development is unknown. In this study, we tested three different hypotheses: an inhibitory role for Gαi proteins in BCR signaling in transitional B cells, an inability of Gαi-deficient transitional B cells to access Notch2 ligand expressing cells, and an intrinsic role for Gαi proteins in Notch2 processing or signaling. This report supports the third hypothesis. Suggesting a defect in Notch2 processing or transcriptional activity both WT and Gαi-deficient transitional B cells expressed similar Notch2 levels, yet the latter exhibited impaired Notch2 signaling. The Gαi-deficient transitional B cells had low levels of CD21 and a reduction in Hes1, Dtx1, and Id2 expression, known Notch2 target genes. Arguing that inadequate access to Notch2 ligands did not account for the MZ B cell development defect, plating Gαi-deficient B cell progenitors directly on a source of Notch ligands did not rescue MZ B cell development. Supporting a defect in Notch processing and/or translocation, the Gαi-deficient transitional B cells had reduced plasma membrane localized ADAM10 and either blocking Gαi nucleotide exchange or the lack of Gαi proteins inhibited progenitor B cells from upregulating ADAM10 expression. Together, these data indicate that Gαi signaling helps supports ADAM10 expression and Notch 2 signaling in transitional B cell.
Notch processing and subsequent transcriptional activity depends upon its cleavage by membrane localized ADAM10. Besides lacking MZ B cells, ADAM10-deficient transitional B cells express low levels of Notch target gene (14) . An ADAM10 processing defect partially accounts for the reduced membrane ADAM10 expression noted in the Gαi-deficient transitional B cells as immunoblots revealed a threefold to fourfold reduction in the mature form of ADAM10. Supporting this observation, anti-IgM did not trigger ADAM10 to translocate to the plasma membrane in the Gαi-deficient T0 and T1 B cells. Subject to multiple layers of regulation, ADAM10 activity requires proprotein convertases within the secretory pathway to cleave the ADAM10 zymogen. This releases the active enzyme and promotes its plasma membrane translocation. Removal of the prodomain depends upon a canonical site for a Furin-mediated cleavage located between the pro-and catalytic domains of ADAM10 (44) . Previous reports have linked ADAM10 processing to GPCR signaling (49) . Most of these studies focused on GPCR engagement triggering ADAM10-mediated EGF receptor transactivation rather than Notch2 activation. For example, treatment of non-transformed N15C6 cells with CXCL12 enhanced ADAM10 prodomain removal and triggered ADAM10-dependent amphiregulin ectodomain shedding (50) . The enhanced ADAM10 activity depended upon Src kinase activity. Both free Gβγ subunits and GTP bound Gαi have been implicated in Src kinase activation (51) . Not only did the Gαi-deficient transitional B cells have reduced membrane ADAM10 expression but so did developing B cells in the bone marrow. Thus, the microenvironmental exposure to chemoattractants in the bone marrow and spleen likely supports the maturation of ADAM10 in developing B cells.
While a processing defect may explain the low ADAM10 membrane expression on the Gαi-deficient transitional B, Gαi signaling also promotes the rapid translocation of ADAM10 to the plasma membrane. Only 5-10% of the wild-type transitional B cells (B220
It is this population that contained MZ, but not FO B cell precursors, and its loss in the Taok3 −/− mice that accounted for the MZ B cell development defect (12) . Like the Taok3 −/− B cells, the Gαi-deficient B had a similar reduction in this population. Since ADAM10 processing occurred normally in the Taok3 −/− transitional B cells, an ADAM10 translocation defect best explained their poor MZ B cell development. In addition, crosslinking surface Ig on wild-type B cells mobilized ADAM10 from intracellular stores to the plasma membrane as assessed by immunohistochemistry (12) . Using flow cytometry, we confirmed that BCR crosslinking increased plasma membrane ADAM10 expression on transitional B cells. Although not as robust as surface IgM crosslinking, the exposure of transitional B cells to CXCL12 also led to increased ADAM10 surface expression. In line with these results, a brief exposure to either anti-Ig or CXCL12 increased the level of pTaok proteins in wild-type T0 and T1 cells.
However, bone marrow cell-derived B cell progenitors behaved differently when exposed to CXCL12 or anti-Ig. A 2-day culture on OP9-DL1 cells upregulated ADAM10 and CD23 expression. Perhaps because the OP9-DL1 cells secrete CXCL12 (52) and likely other GPCR ligands, the addition of exogenous CXCL12 to the OP9-DL1 cultures had no effect. However, pretreating the B cell progenitors with PTX strongly inhibited the induction of ADAM10, reduced CD81 expression, decreased the appearance of T2 B cells, and decreased MZ B cell development. Surprisingly, the addition of anti-IgM also inhibited CD23 upregulation and totally blocked the appearance of T2 cells. While a BTK inhibitor also prevented the appearance of T2 transitional cells, it did not affect ADAM10 or CD81 expression. Based on these studies, both antigen receptor crosslinking and Gi signaling can promote the membrane expression of ADAM10, a necessary step in splenic MZ B cell development. However, the timing and the context of the antigen receptor signal may be important in determining whether newly arrived bone marrow B cells arrest, or further differentiate toward either a FO or MZ B cell.
Signaling pathways triggered by Gαi nucleotide exchange or downstream of BCR engagement cause the translocation of ADAM10 to cell membrane in transitional B cells. They may share or use divergent intermediates to trigger the translocation of ADAM10. Both BCR signaling and CXCR4 engagement enhanced the phosphorylation of Taok proteins, arguing that BCR and Gαi signaling may converge on Taok3 activation, which either directly or indirectly controls the translocation of ADAM10. An intriguing target of Taok3 kinase activity is Mst1 (53) . Taok3 functions in the Hippo pathway both in parallel and upstream of Mst1/2 to activate LATS1/2. In addition, Mst1 is also a known effector triggered by chemokine receptor engagement, whose activation depends upon Gαi signaling. Interestingly, the mst1 −/− mice also have a severe defect in MZ B cell development (54) . It will be of interest to check whether the mst1 −/− transitional B cells also have a reduction in ADAM10 membrane expression.
The eventual target of these signaling pathway must be ADAM10 or an ADAM10 associated protein. Intriguingly, a subgroup of tetraspanins (Tspan5, 10, 14, 15, 17, and 33) that have eight cysteines, referred to as the TspanC8 directly interact with ADAM10 (55) . They affect the exit of ADAM10 from the endoplasmic endothelium, its translocation to the plasma membrane, and even its substrate specificity. Based on their mRNA expression (http://www.immgen.org/databrowser/index.html), the best candidate among the TspanC8 group to control ADAM10 expression in murine transitional B cells is Tspan14. Unfortunately, Tspan14 antibodies are not available for flow cytometry. However, since tetraspanin proteins often interact with other family members to form a tetraspanin web, we checked whether the expression of other family members might correlate with ADAM10 expression on transitional B cells. This led to the findings that the CD81 high transitional B cells also expressed membrane ADAM10 and that the Gαi-deficient transitional B cells, not only expressed less ADAM10, but also less CD81. In agreement with these results, a previous study showed that CD81 can regulate ADAM10-mediated cleavage of TNF-α and epidermal growth factor (56) .
To our knowledge, GPCR or chemoattractant receptor signaling has not been linked to ADAM10 function and Notch signaling in B lymphocytes. Here, we showed that Gαi-deficient transitional B cells have decreased ADAM10 expression and reduced Notch2 target gene expression. Explaining the reduced ADAM10 expression on transitional B cells, we identified both an ADAM10 processing and a translocation defect. We suspect that these may be controlled by separate signaling pathways, likely downstream of different effectors. Reduced or absent Gαi protein expression in developing B cells results in a prolonged absence of input from chemoattractant receptors, which likely supports both ADAM10 expression and processing in developing B cells. By contrast, PTX treatment acutely inhibits Gi signaling by prevents chemoattractant triggered Gαi nucleotide exchange. Normal developing transitional B cells treated with PTX fail to mobilize ADAM10, while stimulation with CXCL12 rapidly mobilized ADAM10 to the cell membrane on a subset of T0/T1 cells. Both chemoattractant and BCR signaling triggered the translocation of ADAM10 from intercellular stores to the plasma membrane perhaps by targeting tetraspanins. Future studies will focus on unraveling the signaling pathways that control the expression, processing, and translocation of ADAM10 in transitional B cells.
eThics sTaTeMenT
This study was carried out in accordance with the recommendations of the NIH Animal Research Advisory Committee (ARAC) guidelines, NIAID Animal Care and Use Committee. The protocol was approved by the NIAID Animal Care and Use Committee.
aUThOr cOnTriBUTiOns I-YH, CB, and JK designed and analyzed the experiments. CB, I-YH, and KH did the experimental work; CB and JK wrote and edited the manuscript. 
